Osteoarthritis

BioElectronics Chairman Updates Investors

Retrieved on: 
Thursday, February 15, 2024
University, Motion, Doctor of Philosophy, OTC, Quality of life, Pain, Dog, Sale, Arthritis, Veterinary medicine, Thumb, Society, Chronic pain, Patient, Knee, Clinical trial, Osteoarthritis, Hand, Stanford University Medical Center, Literature, Twilight anesthesia, UCSD, Research, Audit

FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Key Points: 
  • FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation ( https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.
  • The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans.
  • Today, I will focus on the first of these, although I will briefly mention the two other vital components of our mission.
  • Such findings will be new to the literature and should provide important evidence on reducing opioid use and minimizing post-surgical chronic pain.

Ampio Provides Update on Results from Pre-IND Enabling Studies

Retrieved on: 
Wednesday, February 14, 2024
Drug discovery, Osteoarthritis, Pain, Investigational New Drug, IND, Cartilage, Knee

ENGLEWOOD, Colo., Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity.

Key Points: 
  • ENGLEWOOD, Colo., Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity.
  • Ampio reported that the efficacy results of these studies do not support an Investigational New Drug ("IND") submission which was anticipated in early 2025.
  • The Company's management and the Board are currently assessing both internal and external options.
  • The Company will be taking immediate actions to preserve its cash in order to be able to adequately fund any option identified by the Board.

New HSS Studies Highlight the Benefits of Robotic-Assisted Joint Replacement Surgery

Retrieved on: 
Wednesday, February 14, 2024
SAN, Incidence, Research, Instability, Dislocation, Surgeon, Cohort (statistics), Confusion, MBA, MUA, Risk, MHA, HSS, THR, Anesthesia, Joint stiffness, THA, Knee, Patient, MPH, Osteoarthritis, AAOS, Case Western Reserve University, Robotics, Hip, American Academy, Medical device

Investigators at HSS set out to determine if the use of computer navigation or robotic-arm assistance during surgery reduced the need for MUA.

Key Points: 
  • Investigators at HSS set out to determine if the use of computer navigation or robotic-arm assistance during surgery reduced the need for MUA.
  • "These results highlight the potential benefits of incorporating technological advancements into knee replacement surgery, offering improved outcomes and reducing the need for additional interventions such as MUA," Dr. Jerabek said.
  • The second study compared short-term outcomes of the anterior versus the posterior approach in robotic-assisted total hip replacement (THR) surgery.
  • "As the use of robotic assistance in joint replacement surgery becomes more common, future studies should evaluate outcomes over longer periods of time," concluded Dr. Mayman.

Rejuvenate Bio Announces Partnership with Leading Animal Health Company to Develop Gene Therapy for Canine Osteoarthritis

Retrieved on: 
Wednesday, February 14, 2024
Pets, Technology, Professional Services, Science, Genetics, Veterinary, Consumer, Clinical Trials, FDA, Biotechnology, Health, Other Science, Research, Software, Other Health, Pharmaceutical, Finance, Phibro Animal Health, Inflammation, Quality of life, Euthanasia, Animal, Dog, Overalls, Conditional sentence, Veterinarian, Rejuvenation, OA, Osteoarthritis, Disease, Human, Partnership, Vaccine

Rejuvenate Bio today announced a partnership with a leading animal health company for the development and commercialization of its novel gene therapy technology for the treatment of canine osteoarthritis (OA), a complex chronic disease that affects dogs’ mobility and overall quality of life.

Key Points: 
  • Rejuvenate Bio today announced a partnership with a leading animal health company for the development and commercialization of its novel gene therapy technology for the treatment of canine osteoarthritis (OA), a complex chronic disease that affects dogs’ mobility and overall quality of life.
  • This agreement with the global company follows the agreement reached in 2022 with Phibro Animal Health and further validates the gene therapy technology developed by Rejuvenate Bio and their strategy to develop their breakthrough technology in both animal health and human health.
  • Canine osteoarthritis (OA) presents a significant challenge, being both painful and progressive, with a concerning prevalence rate.
  • “This partnership with a leading animal health company validates our technology and approach of utilizing gene therapy to treat chronic age-related diseases and ensures that this therapy will reach the dogs that need it.

Orthopedic Surgeon Tomas Pevny, MD, of Valley View, Is the First in the Roaring Fork Valley to Offer iovera°, a New Option to Manage Knee Pain

Retrieved on: 
Tuesday, February 13, 2024
MD, Shoulder, FDA, Pain, Hip, Orthopedic surgery, Swelling, Skin, Eagle, Stiffness, Arthritis, Chronic pain, Nursing, Knee, Patient, Elbow, Osteoarthritis, CDC, Sports medicine, Wrist, Motion, Dentistry

GLENWOOD SPRINGS, Colo., Feb. 13, 2024 /PRNewswire/ -- Valley View, the Roaring Fork Valley leader in healthcare technology, is pleased to announce that Orthopedic Surgeon Tomas Pevny, MD, is first in the region to offer iovera°, an FDA-approved, non-surgical, non-opioid osteoarthritis knee pain treatment that uses extreme cold to temporarily stop nerves from sending pain signals.

Key Points: 
  • Osteoarthritis is the most common form of arthritis, affecting 32.5 million United States adults, according to the Centers for Disease Control (CDC).
  • Osteoarthritis is caused by damage or breakdown of joint cartilage between bones, which may cause pain, stiffness, decreased range of motion and swelling.
  • Part of Valley View, ValleyOrtho is committed to being the trusted leader in innovative, quality-focused, comprehensive musculoskeletal care in Aspen, the Roaring Fork Valley and beyond.
  • ValleyOrtho also provides world-class orthopedic surgery at Valley View Hospital in Glenwood Springs and the Valley View Surgery Center in Basalt.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE WESTERN VETERINARY CONFERENCE IN LAS VEGAS, NEVADA

Retrieved on: 
Tuesday, February 13, 2024
Pet, Osteoarthritis, Animal, Joint, Veterinarian, Conference, Arthralgia, WVC, Mandalay Bay Convention Center, Video game

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • WVC is the largest veterinary conference that services the western part of the United States, and normally plays host to more than 15,000+ participants including many of the top industry professionals.
  • “We are incredibly excited to participate in this year’s Western Veterinary Conference.

Zoetis Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 13, 2024
Veterinary, Health, Sarolaner, Acquisition, International, Livestock, Tick, Artificial intelligence, Poultry, Investment, Pig, Pain, Animal, Growth, Dog, Dermatology, Coccidioides immitis, Vaccine, OA, Virus, Webcast, Cat, Osteoarthritis, Inc., Pharmaceutical industry

(NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2023 as well as provided full year guidance for 2024.

Key Points: 
  • (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2023 as well as provided full year guidance for 2024.
  • The company reported revenue of $2.2 billion for the fourth quarter of 2023, which was an increase of 8% compared with the fourth quarter of 2022, on both a reported and operational1 basis.
  • In the fourth quarter of 2023:
    Revenue in the U.S. segment was $1.2 billion, an increase of 9% compared with the fourth quarter of 2022.
  • Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review fourth quarter and full year 2023 results, discuss financial guidance and respond to questions from financial analysts.

AeroBand's New Releases Shine at NAMM Show 2024, Garnering Rapid Popularity

Retrieved on: 
Thursday, February 8, 2024
Internet, Instrument, Multimedia, Lead, NAMM, Electronics, Interview, AUX, Logic Pro, OA, Music, Incidence, NAMM Show, Frontiers in Medicine, Singing, Osteoarthritis, Jean Sibelius, Social media, Smartphone, Learning, Reproduction, Hand, Motivation, Cassette tape

For individuals with finger ailments and sensitivity, including children and the elderly, this breakthrough technology opens up musical possibilities for a wider audience.

Key Points: 
  • For individuals with finger ailments and sensitivity, including children and the elderly, this breakthrough technology opens up musical possibilities for a wider audience.
  • For beginners and those who had previously given up learning the guitar, AeroBand Guitar undoubtedly addresses the pain issue during practice.
  • During the Premier Guitar interview , the AeroBand team showcased a unique application designed specifically for the AeroBand Guitar.
  • At this year's NAMM Show, AeroBand takes the lead and showcases the highly anticipated product - PocketDrum 2 Plus.

PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy

Retrieved on: 
Wednesday, February 7, 2024
Trial of the century, Therapy, Limp, Safety, Joint, Pain, Shoulder, Synovial joint, Animal, Osteoarthritis, Cat, Arthralgia, Hip, Elbow

Spryng™ with OsteoCushion™ Technology) into the joints of cats.

Key Points: 
  • Spryng™ with OsteoCushion™ Technology) into the joints of cats.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
  • The data provided demonstrated the excellent safety profile of Spryng when injected IA into 40 joints (10 each, shoulder, hip, elbow, stifle) across 10 individual cats.

Danish dog owners are medicating their pets with unlicensed cannabis products – is it safe?

Retrieved on: 
Tuesday, February 6, 2024
Anxiety, Attention, Cannabis, Cannabidiol, Chronic pain, Travel, THC, Migraine, Research, Edible, Toxicity, Lethargy, Safety, Food, Dog, Oil, Cannabinoid, Osteoarthritis, Skin, Saliva, Thought, Pain management, Vomiting, Cat, Allergy, Health, Diarrhea, Pet, Medical imaging

Unsurprisingly, this trend has made its way to our pets, with a recent study suggesting that 38% of surveyed Danish dog owners routinely gave their pets some form of cannabis product.

Key Points: 
  • Unsurprisingly, this trend has made its way to our pets, with a recent study suggesting that 38% of surveyed Danish dog owners routinely gave their pets some form of cannabis product.
  • Previous studies suggest that 80% of dog owners in the US and Canada had bought cannabis products for their pet.
  • But, is CBD safe for our pets and could it be a useful addition to our pet’s healthcare regime?
  • Indeed, 36% of respondents in the Danish study indicated that they used cannabinoids for pain management in their pets.